Top

Published in:

Open Access 01-12-2011 | Original Paper

Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro

Authors: Martin W. Elmlinger, Martin Kriebel, Dan Ziegler

Published in: NeuroMolecular Medicine | Issue 4/2011

Abstract

The recently described therapeutic benefits of the hemodialysate actovegin on neuropathic symptoms in diabetic patients with symptomatic polyneuropathy suggest a neuroprotective activity of the drug. To elucidate the possible cellular mechanism of the pharmacological effects of actovegin, we investigated its effects on cultured primary rat neurons in vitro. Primary neurons were cultured for up to 10 days in the presence of increasing doses of actovegin (0.3–1,000 mg/l). Total cell number, dendrite length and the number of excitatory synapses, i.e., the amount of the synaptic V-Glut1 protein, were measured by immunocytochemistry followed by fluorescence microscopy. The apoptotic level in neurons after induction of apoptosis by amyloid peptide Aβ_25–35 was assessed by the level of activated caspase-3. In addition, the capability of the neurons to diminish oxidative stress was assessed by measuring the cellular level of reactive oxygen species ROS in the presence of actovegin. Actovegin treatment yielded an increased maintenance of neuronal cells and total number of synapses and could lower the level of activated caspase-3 in a dose-dependent manner. Dendrite lengths were not significantly affected. In addition, actovegin reduced the cellular level of ROS in cultured neurons. The cellular effects observed suggest neuroprotective and anti-oxidative effects of the drug Actovegin^®, which could at least partially explain its therapeutic benefits.

Araujo, I. M., Ambrosio, A. F., et al. (2004). Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: A comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2–024 and BIA 2–093. Epilepsia, 45(12), 1498–1505.PubMedCrossRef

Beiswenger, K. K., Calcutt, N. A., & Mizisin, A. P. (2008). Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neuroscience Letter, 442, 267–272.CrossRef

Bianchi, R., Buyukakilli, B., Brines, M., Savino, C., Cavaletti, G., Oggioni, N., et al. (2004). Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the USA, 101, 823–828.PubMedCrossRef

Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., et al. (2005). Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care, 28, 956–962.PubMedCrossRef

Buchmayer, F., Pleiner, J., Elmlinger, M. W., Lauer, G., Neel, G., & Sitte, H. H. (2011). Actovegin^®: A biological drug for more than 5 decades. Wiener Medizinische Wochenschrift, 161(3–4), 80–88.PubMedCrossRef

Burkarth, N., Kriebel, M., Kranz, E. U., & Volkmer, H. (2007). Neurofascin regulates the formation of gephyrin clusters and their subsequent translocation to the axon hillock of hippocampal neurons. Molecular and Cellular Neuroscience, 36, 59–70.PubMedCrossRef

Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995). Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron, 14, 879–888.PubMedCrossRef

Cambon, K., Hansen, S. M., Venero, C., Herrero, A. I., Skibo, G., Berezin, V., et al. (2004). A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation. Journal of Neuroscience, 24, 4197–4204.PubMedCrossRef

Cameron, N. E., Cotter, M. A., Horrobin, D. H., & Tritschler, H. J. (1998). Effects of alpha-lipoic acid on neurovascular function in diabetic rats: Interaction with essential fatty acids. Diabetologia, 41(4), 390–399.PubMedCrossRef

Cameron, N. E., Eaton, S. E., Cotter, M. A., & Tesfaye, S. (2001). Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44, 1973–1988.PubMedCrossRef

Chalk, C., Benstead, T. J., & Moore, F. (2007). Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. The Cochrane Database of Systematic Reviews, 4, CD004572.PubMed

Cheng, G., Whitehead, S. N., et al. (2006). Effects of pyrrolidine dithiocarbamate on beta-amyloid (25–35)-induced inflammatory responses and memory deficits in the rat. Neurobiology of Diseases, 23(1), 140–151.CrossRef

de Groot, H., Brecht, M., & Machicao, F. (1990). Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract. Esearch Communications in Chemical Pathology and Pharmacology, 68(1), 125–128.

Dumont, M., & Beal, M. F. (2011). Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine, 51(5), 1014–1026.PubMedCrossRef

Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., et al. (2007). Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain, 132, 237–251.PubMedCrossRef

Goetze, B., Grunewald, B., Kiebler, M.A., & Macchi, P. (2003). Coupling the iron-responsive element to GFP–an inducible system to study translation in a single living cell. Sci STKE, (204), PL12.

Herrmann, W. M., Bohn-Olszewsky, W. J., & Kuntz, G. (1992). Infusionstherapie mit Actovegin bei Patienten mit primärer degenerativer Demenz vom Alzheimertyp und Multiinfarktdemenz. Ergebnisse einer prospektiven, placebo-kontrollierten Doppelblindstudie bei stationären Patienten. Z. Geriatrie, 5, 46–55. Article in German.

Jacob, S., Dietze, G. J., Machicao, F., Kuntz, G., & Augustin, H. J. (1996). Improvement of glucose metabolism in patients with type II diabetes after treatment with a hemodialysate. Arzneimittelforschung, 46, 269–272.PubMed

Kanowski, S., Kinzler, E., Lehmann, E., Schweizer, A., & Kuntz, G. (1995). Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiatry, 28(4), 125–133.PubMedCrossRef

Klementiev, B., Novikova, T., Novitskaya, V., Walmod, P. S., Dmytriyeva, O., Pakkenberg, B., et al. (2007). A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta_25–35. Neuroscience, 145(1), 209–224.PubMedCrossRef

Kubo, T., Nishimura, S., et al. (2002). In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1–40) to truncated and toxic fragments ([D-Ser 26]A beta 25–35/40) and fragment presence in the brains of Alzheimer’s patients. Journal of Neuroscience Research, 70(3), 474–483.PubMedCrossRef

Maar, T. E., Rønn, L. C., Bock, E., Berezin, V., Moran, J., Pasantes-Morales, H., et al. (1997). Characterization of microwell cultures of dissociated brain tissue for studies of cell–cell interactions. Journal of Neuroscience Research, 47, 163–172.PubMedCrossRef

Maurice, T., Su, T. P., et al. (1998). Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25–35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience, 83(2), 413–428.PubMedCrossRef

Neiiendam, J. L., Køhler, L. B., Christensen, C., Li, S., Pedersen, M. V., Ditlevsen, D. K., et al. (2004). An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. Journal of Neurochemistry, 91, 920–935.PubMedCrossRef

Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., et al. (2001). Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 60(8), 759–767.PubMed

Obermaier-Kusser, B., Mühlbacher, C., Mushack, J., Seffer, E., Ermel, B., Machicao, F., et al. (1989). Further evidence for a two-step model of glucose-transport regulation Inositol phosphate-oligosaccharides regulate glucose-carrier activity. Biochemical Journal, 261, 699–705.PubMed

Pike, C. J., Walencewicz-Wasserman, A. J., et al. (1995). Structure-activity analyses of beta-amyloid peptides: Contributions of the beta 25–35 region to aggregation and neurotoxicity. Journal of Neurochemistry, 64(1), 253–265.PubMedCrossRef

Ronn, L. C., Ralets, I., Hartz, B. P., Bech, M., Berezin, A., Berezin, V., et al. (2000). A simple procedure for quantification of neurite outgrowth based on stereological principles. Journal of Neuroscience Methods, 100(1–2), 25–32.PubMedCrossRef

Saletu, B., Grünberger, J., Linzmayer, L., Anderer, P., & Semlitsch, H. V. (1990). EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative Actovegin: Double-blind, placebo-controlled trials. Neuropsychobiology, 24(3), 135–148.PubMedCrossRef

Schlaffer, K., Wauschkuhn, C. H., & Hauser, B. (1991). Study to evaluate the encephalotropic potency of a hemodialysate. Controlled study using electro-retinography and visual evoked potentials under hypoxic conditions in human volunteers (preliminary communication). Arzneimittelforschung, 41, 699–704.

Semlitsch, H. V., Anderer, P., Saletu, B., & Hochmayer, I. (1990). Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsycho-Biology, 24(1), 49–56.CrossRef

Skibo, G. G., Lushnikova, I. V., Voronin, K. Y., Dmitrieva, O., Novikova, T., Klementiev, B., et al. (2005). A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo. European Journal of Neuroscience, 22(7), 1589–1596.PubMedCrossRef

Stepanichev, M. Y., Moiseeva, Y. V., et al. (2003a). Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats. Brain Research Bulletin, 61(2), 197–205.PubMedCrossRef

Stepanichev, M. Y., Zdobnova, I. M., et al. (2003b). Effects of tumor necrosis factor-alpha central administration on hippocampal damage in rat induced by amyloid beta-peptide (25–35). Journal of Neuroscience Research, 71(1), 110–120.PubMedCrossRef

Trubetskaya, V. V., Stepanichev, M. Y., et al. (2003). Administration of aggregated beta-amyloid peptide (25–35) induces changes in long-term potentiation in the hippocampus in vivo. Neuroscience and Behavioral Physiology, 33(2), 95–98.PubMedCrossRef

Walicke, P., Cowan, W. M., et al. (1986). Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. Proceedings of the National Academy of Sciences of the USA, 83(9), 3012–3016.PubMedCrossRef

Ziegler, D. (2008). Treatment of diabetic neuropathy and neuropathic pain: How far have we come? Diabetes Care, 31(2), S255–S261.PubMedCrossRef

Ziegler, D., Hanefeld, M., Ruhnau, K. J., Meißner, H. P., Lobisch, M., Schütte, K., et al. (1995). The ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant-lipoic acid: A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38, 1425–1433.PubMedCrossRef

Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis. Diabetic Medicine, 21(2), 114–121.PubMedCrossRef

Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., et al. (2006). Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care, 29(11), 2365–2370.PubMedCrossRef

Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., & Mielck, A. (2008). The KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: The MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care, 31, 464–469.PubMedCrossRef

Ziegler, D., Movsesyan, L., Mankovsky, B., Gurieva, I., Abylaiuly, Z., & Strokov, I. (2009). Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care, 32, 1479–1484.PubMedCrossRef

Title: Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro
Authors: Martin W. Elmlinger
Martin Kriebel
Dan Ziegler
Publication date: 01-12-2011
Publisher: Humana Press Inc
Published in: NeuroMolecular Medicine / Issue 4/2011
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-011-8157-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Next-Generation Sequencing Reveals Regional Differences of the α-Synuclein Methylation State Independent of Lewy Body Disease

Brain Iron Dysregulation and the Risk of Ageing White Matter Lesions

Proteomic CNS Profile of Delayed Cognitive Impairment in Mice Exposed to Gulf War Agents

Brain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond

Association Study of Brain-Derived Neurotrophic Factor Gene Polymorphisms and Body Weight Change in Schizophrenic Patients Under Long-Term Atypical Antipsychotic Treatment

Chronic Dichlorvos Exposure: Microglial Activation, Proinflammatory Cytokines and Damage to Nigrostriatal Dopaminergic System